Quanterix Corporation Earnings Recaps
Q1 2026
May 7, 2026
Quanterix shares dropped 16.7% after earnings as investors reacted negatively to softer-than-expected instrumentation sales and a cautious near-term outlook, despite ongoing investments and operational changes that have yet to deliver clear growth.
Key takeaways
- Q1 revenue totaled $36.4 million, with consumable sales meeting plans but instrumentation revenue coming in below expectations.
- Management attributed weaker instrument sales partially to timing issues but acknowledged the need for sharper sales focus and commercial investments.
- The company is increasing investments in leadership and go-to-market capabilities to drive pharma partnerships and new business development.
- Gross margins and cash usage targets were maintained, reflecting operational discipline despite top-line pressures.
- Quanterix emphasized long-term growth initiatives, particularly in Alzheimer’s diagnostics, but these remain early-stage without immediate financial impact.
Q3 2025
Nov 11, 2025
Quanterix Corporation reported a solid Q3 2025 performance with $40.2 million in revenue, marking a 12% year-over-year increase and demonstrating effective integration post-Akoya acquisition.
Key takeaways
- Achieved $67 million of the targeted $85 million in cost synergies from the Akoya acquisition within just over three months.
- Instrumentation and accelerator revenues showed sequential growth, signaling potential market stabilization.
- Invested approximately $27 million in R&D, underlining commitment to innovation, particularly in Alzheimer's diagnostics.
- On track to maintain a strong cash position with projected year-end cash of around $120 million and no debt.
- Early success in commercial synergy with growing interest in multimodal biomarker strategies among customers.